Form 4: Nautilus Biotech GC Granted 160,000 Stock Options

Nautilus Biotechnology's General Counsel, Matthew B. Murphy, was granted 160,000 stock options with an exercise price of $2.32, vesting over four years.

Summary

• Matthew B. Murphy, General Counsel of Nautilus Biotechnology, Inc. (NAUT), was granted 160,000 stock options.
• The options have an exercise price of $2.32 per share.
• The transaction date for the option grant was March 2, 2026.
• The options expire on March 2, 2036.
• Vesting commenced on January 1, 2026, with 25% of the shares vesting on the one-year anniversary (January 1, 2027).
• One thirty-sixth (1/36th) of the remaining shares will vest each month thereafter.
• Vesting is contingent upon Mr. Murphy's continuous status as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.
• Following this transaction, Mr. Murphy beneficially owns 160,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as the grant of stock options aligns the General Counsel's long-term interests with those of shareholders, incentivizing future company performance.

Positives

• The grant of stock options aligns the General Counsel's long-term interests with those of shareholders, incentivizing future company performance and stock price appreciation.
• The options were granted at an exercise price of $2.32, providing a clear target for value creation.

Negatives

• The options do not represent immediate ownership of common stock and their value is contingent on the stock price exceeding the exercise price.
• There is no immediate cash benefit to the reporting person from this grant.

Risks

• The value of the stock options is dependent on the future market price of Nautilus Biotechnology, Inc. common stock exceeding the exercise price of $2.32 per share; if the stock price remains below this level, the options may become worthless.
• Options may be forfeited if the reporting person's continuous status as a 'Service Provider' is not maintained through each vesting date, as per the terms of the 2021 Equity Incentive Plan.

Future Outlook

The stock option grant incentivizes the General Counsel to contribute to the long-term growth and success of Nautilus Biotechnology, Inc., aligning their future financial interests with the company's performance and shareholder value creation.

Industry Context

StockSavvy.ai notes that granting stock options to key executives is a standard practice in the biotechnology industry and broader corporate landscape. This compensation structure is designed to attract, retain, and motivate talent by linking executive rewards directly to the company's stock performance and long-term value creation, which is particularly common in growth-oriented sectors like biotech.

Comparison to Industry Standards

• The structure of this option grant, including a multi-year vesting schedule and an exercise price set at the market price on the grant date, is consistent with typical executive compensation practices observed across the biotechnology and technology sectors.
• Companies such as Illumina (ILMN) and Pacific Biosciences of California (PACB), also in the genomics and biotechnology tools space, frequently utilize similar equity incentive plans to compensate and retain key personnel.

Stakeholder Impact

• Shareholders: The grant aligns management's incentives with shareholder interests, potentially leading to increased focus on long-term stock price appreciation.
• Employees: This grant is part of the company's overall compensation strategy, which can influence employee morale and retention, particularly for key personnel.

Next Steps

• The options will begin to vest on January 1, 2027, with subsequent monthly vesting thereafter, contingent on continuous employment.

Key Dates

Keywords

Nautilus Biotechnology, NAUT, stock options, executive compensation, Form 4, insider transaction, equity incentive plan, vesting